Your browser doesn't support javascript.
loading
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study.
Brüggen, M-C; Valencak, J; Stranzenbach, R; Li, N; Stadler, R; Jonak, C; Bauer, W; Porkert, S; Blaschke, A; Meiss, F; Nicolay, J P; Wehkamp, U; Schlaak, M; Nguyen, V A; Romani, N; Cozzio, A; Gayathri, N; Dimitriou, F; French, L E; Dummer, R; Guenova, E.
Afiliação
  • Brüggen MC; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
  • Valencak J; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Stranzenbach R; Medical Campus Davos, Davos, Switzerland.
  • Li N; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Stadler R; Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Minden, Germany.
  • Jonak C; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
  • Bauer W; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Porkert S; Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Minden, Germany.
  • Blaschke A; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Meiss F; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Nicolay JP; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Wehkamp U; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Schlaak M; Department of Dermatology and Venereology, Faculty of Medicine, University Medical Center - University of Freiburg, Freiburg, Germany.
  • Nguyen VA; Department of Dermatology, Venereology and Allergology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
  • Romani N; Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Cozzio A; Department of Dermatology and Venereology, University Hospital of Cologne, Cologne, Germany.
  • Gayathri N; Department of Dermatology and Allergology, Ludwig-Maximilians-University of Munich, Munich, Germany.
  • Dimitriou F; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
  • French LE; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
  • Dummer R; Department of Dermatology, Venereology and Allergology, Canton Hospital of St. Gallen, St. Gallen, Switzerland.
  • Guenova E; Department for Hematology, University Hospital of Zurich, Zurich, Switzerland.
J Eur Acad Dermatol Venereol ; 34(7): 1489-1495, 2020 Jul.
Article em En | MEDLINE | ID: mdl-31955469
ABSTRACT

BACKGROUND:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive type of haematologic precursor malignancy primarily often manifesting in the skin. We sought to provide a thorough clinical characterization and report our experience on therapeutic approaches to BPDCN.

METHODS:

In the present multicentric retrospective study, we collected all BPDCN cases occurring between 05/1999 and 03/2018 in 10 secondary care centres of the German-Swiss-Austrian cutaneous lymphoma working group.

RESULTS:

A total of 37 BPDCN cases were identified and included. Almost 90% of the patients had systemic manifestations (bone marrow, lymph nodes, peripheral blood) in addition to skin involvement. The latter presented with various types of cutaneous lesions nodular (in more than 2/3) and bruise-like (in 1/3) skin lesions, but also maculopapular exanthema (in circa 1/6). Therapeutically, 22 patients received diverse combinations of chemotherapeutic regimens and/or radiotherapy. Despite initial responses, all of them ultimately relapsed and died from progressive disease. Eleven patients underwent haematopoietic stem cell transplantation (HSCT; autologous HSCT n = 3, allo-HSCT n = 8). The mortality rate among HSCT patients was only 33.33% with a median survival time of 60.5 months.

CONCLUSION:

Our study demonstrates the clinical diversity of cutaneous BPDCN manifestations and the positive development observed after the introduction of HSCT.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Hematológicas Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Hematológicas Idioma: En Ano de publicação: 2020 Tipo de documento: Article